Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines – A prospective multi-center study
Pawat Phuensan(Thai Red Cross Society), Rungsun Rerknimitr(Chulalongkorn University)
Cited by 6